Helsinn Therapeutics (U.S.)
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Helsinn Therapeutics (U.S.) sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).
Helsinn Therapeutics (U.S.): 10 sponsored US clinical trials, none currently recruiting.
Helsinn Therapeutics (U.S.) sponsors 10 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 10 completed. 3 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Gastrointestinal Dysmotility, with 1 trials.
Top-decile sponsor footprint
Helsinn Therapeutics (U.S.) ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
10 of 10 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
10 total, page 1 of 1
Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma
NCT02296164
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)
NCT01387282
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)
NCT01387269
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
NCT01395914
Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function
NCT01280344
Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus
NCT00672074
Dose Range Study of Anamorelin in Patients With Non-small Cell Lung Cancer
NCT00622193
Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia
NCT00378131
Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia.
NCT00267358
Safety and Efficacy of RC-1291 HCl in Patients With Cancer Related Anorexia and Weight Loss
NCT00219817
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 6 |
| Phase 3 | 3 |
Therapeutic Areas
How the Helsinn Therapeutics (U.S.) early-phase archive is shaped
10 indexed studies, none listed as recruiting (0% open); 10 completed (100%).
Phase mix: 3 late (III/IV) vs 6 early (I/II) (early-phase heavy).
Top condition: Gastrointestinal Dysmotility (1 trial), 3 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Helsinn Therapeutics (U.S.): archived-pipeline peers nationwide
Peers matched on 10 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Helsinn Therapeutics (U.S.) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 10 archived trials
- Adamas Pharmaceuticals · 10 trials · 0% recruiting
- Adverum Biotechnologies · 10 trials · 30% recruiting
- Aevi Genomic Medicine, LLC, a Cerecor company · 10 trials · 0% recruiting
- Agouron Pharmaceuticals · 10 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Helsinn Therapeutics (U.S.) page
10 registered trials is a research-attention snapshot, not an endorsement of Helsinn Therapeutics (U.S.) or any single study.
- None of Helsinn Therapeutics (U.S.)'s trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Gastrointestinal Dysmotility is the condition Helsinn Therapeutics (U.S.) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Gastrointestinal Dysmotility trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Helsinn Therapeutics (U.S.) pipeline card: 10 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.